Our Clinical Trials system is temporarily offline. Sorry for any inconvenience this may cause.
NCT ID | Study Title | Action |
---|---|---|
NCT01219829 | Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma | View |
NCT01821729 | Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer | View |
NCT00294840 | Dynamic PET acquisition-a Quantitative Technique for Grading of Malignant Tumors and Prediction of Response to Treatment | View |
NCT03407040 | Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy | View |
NCT00365144 | Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine | View |
NCT03457844 | A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 | View |
NCT02584244 | Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | View |
NCT06980792 | Surgical Approach for Adenocarcinoma of the Pancreas With Synchronous Liver Metastases | View |
NCT00252889 | Doxil Topotecan Doublet Cancer Study | View |
NCT03703089 | Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology | View |
NCT02570529 | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy | View |
NCT02608229 | BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | View |
NCT01942629 | Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas | View |
NCT03686592 | Psychological Effect of the pancréatectomy: a Feeling of Strangeness | View |
NCT04498689 | Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | View |
NCT04571489 | A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer | View |
NCT02000089 | The Cancer of the Pancreas Screening-5 CAPS5)Study | View |
NCT02194829 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | View |
NCT06079229 | Quality of Life in Elderly Patients After Pancreatic Cancer Surgery | View |
NCT02818829 | Biological and Clinical Database for Pancreatic Adenocarcinoma | View |
NCT00901680 | Creation of the BioBank, Early Detection and Discovery Biomarkers | View |
NCT04892329 | A Multi-center Study on the Efficacy and Safety of AI-assisted Navigation System for Biliopancreatic EUS | View |
NCT02175992 | Quality of Life After Surgery for Pancreatic Carcinoma | View |
NCT01078662 | Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats | View |
NCT04105062 | LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery | View |
National Pancreatic Cancer Foundation provides access to clinical research studies. This information is provided by clinicaltrials.gov and is maintained by the National Library of Medicine (NLM). Neither NPCF nor the US government review or approve the safety and science of the studies on this website. Read the disclaimer for details.Â
NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.
The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.